China Medical System: New Drug Application of Desidustat Tablets Accepted in China
- Desidustat Tablets are novel, oral HIF-PHI for treating anaemia in non-dialysis adult chronic kidney disease patients. The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unmet treatment needs in the field of CKD anaemia, including both dialysis and non-dialysis patients.
- China Phase III trial of the Product has demonstrated positive results. The primary endpoint has indicated that Desidustat is more effective than placebo in increasing Hb level.
- Currently, 4 innovative drugs of CMS have entered into commercialization stage. Meanwhile, continuous advance of products’ clinical development and registration process such as Desidustat Tablets is expected to enrich the Group’s marketed innovative product portfolio, and generate new driving force to the Group’s sustainable and healthy development.
SHENZHEN, CHINA, Apr 23, 2024 – (ACN Newswire) – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 22 April 2024, the New Drug Application (NDA) of Desidustat Tablets (“Desidustat Tablets” or the “Product”) has been accepted by the National Medical Products Administration of China (NMPA). The Product is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in non-dialysis adult, Chronic Kidney Disease (CKD) patients.
CKD involves the gradual loss of functioning of kidneys and eventually leads to kidney failure. If kidneys are healthy, they will naturally secrete beneficial levels of a hormone called Erythropoietin (EPO), which encourages red blood cell production. If the kidneys are impaired, they will produce reduced levels or tire of EPO production completely, leading to anaemia. HIF-PHI promotes erythropoiesis through increasing endogenous erythropoietin, improving iron availability and reducing hepcidin.
It is estimated that more than 120 million people are living with CKD in China[1]. Anaemia is one of the frequent complications of CKD. A survey in China showed that the prevalence of anaemia in patients at CKD stage 1 to 5 were 22.0%, 37.0%, 45.4%, 85.1%, and 98.2%, respectively[2]. The target-achieving rate (the haemoglobin (Hb) level reaching the target value (110~120g / L)) was only 8.2% for anaemia patients in non-dialysis CKD and 35.2% for haemodialysis CKD, showing a large unmet healthcare need[3].
China Phase III trial of the Product has demonstrated positive results. The primary endpoint of the Hb mean change from baseline to the period of Week 7-9 has indicated that, Desidustat is more effective than placebo in increasing Hb level. The least squares mean and 95% CI of Hb change from baseline to the period of Week 7-9, using covariance model analysis, has shown an increase of 16.38 g/l [95%CI: 14.50, 18.26] in the Desidustat group and a decrease of 1.13 g/l [95%CI: -3.68, 1.41] in the placebo group, for a between-group difference of 17.52 g/l [95%CI:14.353, 20.681], with the lower limit of 95% CI above 0.
The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unmet treatment needs in the field of CKD anaemia, including both dialysis and non-dialysis patients. Desidustat Tablets have been approved for marketing in India.
CMS INTERNATIONAL DEVELOPMENT AND MANAGEMENT LIMITED, a wholly-owned subsidiary of the Group, obtained an exclusive license for the Product from Zydus Lifesciences Limited (earlier known as Cadila Healthcare Limited) on 20 January 2020.
Reference:
1. ZhangL, WangF, WangL, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818):815-822. DOI: 10.1016/S0140-6736(12)60033-6
2. Chinese expert consensus on diagnosis and therapy of renal anaemia (the 2014 revised edition), Chinese Journal of Nephrology, 2014;30:712-716
3. Chinese expert consensus on diagnosis and therapy of renal anaemia (the 2018 revised edition), Chinese Journal of Nephrology, 2018, 34(11): 860-866
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Website: https://web.cms.net.cn/en/home/
Expanding its footprint in the healthcare industry, expEDIum is excited to announce the successful collaboration with Long-Term Care Medical Group, Inc. The partnership, initiated in October 2022, has flourished into a dynamic relationship, with Ms. Balwinder Bains, owner of the Medical Billing Service from Fresno, California, leading the charge in seeking innovative solutions to transform their medical billing processes. Facing the challenge of transitioning from a fragmented, legacy system to a more efficient, easily trainable, and scalable solution, Ms. Irene & Balwinder turned to expEDIum for their expertise. After an extensive period of calls and demonstrations, expEDIum gained a deep understanding of their unique needs, identifying a shift in their requirements towards a secure, standards-based, cloud-based system with enhanced features and billing capabilities. The goal was to optimize the total cost of ownership while scaling up operations to handle more patients and process claims efficiently, thereby accelerating revenue generation. After a meticulous evaluation process, Long-Term Care Medical Group, Inc. chose the expEDIum Medical Billing software, making an informed decision only after taking advantage of 60-day free trial feature. Since then, valued client has achieved remarkable results, efficiently processing over 150K claims and over 0.5M HIPAA transactions through eMB in just a year. The total value of the processed claims exceeded $36M, leading to successful reimbursements of over $9M. “We have been utilizing expEDlum for our medical billing needs, and the impact on our business has been nothing short of revolutionary. This cutting-edge software has streamlined our processes, significantly increasing the efficiency of our claim submissions. As a result, we’ve been able to process a higher volume of claims, ultimately expanding our capacity to serve more clients. The user-friendly interface and robust features have truly elevated our operational capabilities, making expEDlum an indispensable asset to our medical billing company,” stated Ms. Balwinder K Bains, General Manager | Credentialing Coordinator, Medical Billing Services. Over the past year and a half, expEDIum has tailored solutions to accommodate the specific needs of each provider. This includes support for 30 billing providers, 70+ rendering providers, 500+ facilities, 725+ referring providers, and 15 ambulance facilities. Currently, about 30 active billers/users across different geographies have processed more than 150K claims, with a significant focus on Medicare of Northern California, Medi-CAL, and Blue Cross of California, though claims are being sent to over 600 payers, out of which 98% electronically with the remaining 2% on Paper. The success story of this partnership has been captured in a detailed case study, highlighting the transformative impact of expEDIum’s solutions on the biller’s operations and revenue generation. Ms. Komal Pradhan, Senior Executive, Business Development from expEDIum, mentioned that “Our top priority has always been the satisfaction of our valued clients, and we are delighted to have consistently delivered on this commitment over several months. We are looking forward to ensuring a continuous and prosperous partnership.” Celebrating these accomplishments, expEDIum looks forward to fostering a continued and thriving relationship with Long-Term Care Medical Group, Inc. The success of this collaboration underscores expEDIum’s commitment to delivering cutting-edge solutions that drive efficiency, scalability, and financial success for healthcare providers & billers. For more information about expEDIum and healthcare solutions, please visit www.expedium.net. About Medical Billing Services: About expEDIum: Ms Komal Pradhan, Senior Executive – Business Development expEDIum Categories China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 2 February 2024, the Group through its wholly-owned subsidiary entered into a Novation Agreement (the “Novation Agreement”) with Vifor Fresenius Medical Care Renal Pharma Ltd. (“VFMCRP”) and Winhealth Investment (HK) Limited (“Winhealth Investment”) for sucroferric oxyhydroxide chewable tablets Velphoro® (the “Product”). Winhealth Investment and VFMCRP entered into a License Agreement (the “License Agreement”) for the Product on 28 June 2023. In accordance with the License Agreement, Winhealth Investment gained an exclusive license to register，import, promote, distribute, use and sell the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region and Taiwan Region (the “Territory”). The License Agreement commenced on its effective date and continues to be valid until the fifteenth anniversary of the date of the Product’s first commercial sale in the Territory. Upon the expiration of the aforementioned term, the License Agreement may automatically be renewed for ten years as per certain conditions defined in the License Agreement. Thereafter, unless the parties reach a new agreement, the License Agreement will terminate upon expiration. In accordance with the Novation Agreement, Winhealth Investment novated its above-mentioned rights and obligations for the Product to a wholly-owned subsidiary of CMS. Velphoro® (Sucroferric Oxyhydroxide Chewable Tablets ) As of 2 February 2024, the Product is the first iron-based, non-calcium phosphate binder (PB) approved by National Medical Products Administration (NMPA) in China1, filling the gap of phosphorus-lowering treatment for Chinese paediatric patients aged 12 to 18 years old with CKD stages 4-5 or CKD on dialysis. Velphoro® is a Class 5.1 imported innovative drug, which was approved through the priority review and approval procedure in China in February 2023 for the control of serum phosphorus (sP) levels in adults with chronic kidney disease (CKD) on hemodialysis (HD) or peritoneal dialysis (PD), and meanwhile, for the control of sP levels in paediatric patients 12 years of age and older with CKD stages 4-5 (defined as glomerular filtration rate <30mL/min/1.73 m²) or CKD on dialysis. The Product has been newly included in category B of China’s National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2023 Version) (the “National Reimbursement Drug List”). There is an issued patent that protects the formulation, usage, particle size and manufacturing methods of the Product in China. Hyperphosphatemia is a common complication in CKD patients, especially in patients with end-stage renal disease on dialysis, characterized by a high morbidity and a low compliance rate. It is an independent risk factor for nephropathy progression, secondary hyperparathyroidism, cardiovascular events and all-cause mortality in CKD patients2. Controlling sP levels can significantly improve the outcomes of CKD patients. Since non-calcium PB has no risk of vascular calcification, domestic and foreign guidelines consistently recommend non-calcium PB as first-line treatment for reducing sP levels, and limit the use of calcium-based PB. Velphoro® is a new generation of iron-based, non-calcium PB, reducing sP levels of patients and increasing the sP compliance rate. Velphoro® has been launched in 51 countries/territories including the US, EU and Japan, maintaining a leading position in the global PB market. It is demonstrated in multiple global clinical studies and real-world research data (as published in academic journals including International Urology and Nephrology, and Clinical Nephrology) and the Chinese instruction of the Product that compared with other PBs, patients maintained on Velphoro® used about 50% fewer PB pills/day3, and the proportion of patients achieving target sP increased by 95%4. Velphoro® has characteristics of good safety5 and patient compliance6 without risk of calcium and heavy metal accumulation. In addition, the Product holds the advantages of unaffected absorption of oral liposoluble vitamin D7, maintaining stable iron parameters8, improving the nutritional status in patients9, reducing hospitalization rates, and alleviating patients’ medical financial burdens10. Velphoro® is expected to further improve the dialysis patients’ quality of life and become a new option of phosphorus-lowering treatment for CKD dialysis patients in China. CMS continues to invest in and develop differentiated innovative products, providing a continuous source of momentum for the long-term and stable development of the Group. Velphoro® is a newly approved innovative drug in China in 2023 and has been successfully included in category B of the National Reimbursement Drug List. It will rapidly expand the Group’s marketed innovative product portfolio and kidney disease product portfolio, and will synergize with the Group’s marketed products XinHuoSu (recombinant human brain natriuretic peptide for injection), Plendil (felodipine sustained-release tablets) and the innovative drug Desidustat tablets (intended to treat anemia in CKD patients) which is in the clinical development stage for registration in terms of expert network and market resources. It is expected to have a positive impact on the Group’s financial results. More information about Hyperphosphatemia The total number of CKD patients reaches 132 million in China, of which nearly 1 million existing patients receive dialysis treatments11, and continues to increase at a rate of approximately 10% per year. The prevalence of hyperphosphatemia reaches 72.1%12 in CKD patients on dialysis, and nearly 50% of dialysis patients need to receive oral PB to control sP levels13. According to the survey in Chinese patients with chronic kidney disease-mineral and bone disorder, combined with real-world findings, on the basis of existing phosphate-lowering treatments, the sP compliance rate of CKD dialysis patients in China is only 24.3%14. The low sP compliance rate is currently the clinical pain point of hyperphosphatemia, and there is an urgent need for more potent drugs with lower pill burden and better adherence to satisfy the clinical treatment demand of hyperphosphatemia. Reference 1. This news/article is intended to share cutting-edge medical information. It is only for reference by medical and health professionals for academic purposes and is not for advertising purposes; it does not recommend any drugs, medical devices and/or indications. Media Contact
Swedish Medical Center, part of HealthONE, announced that the HCA Healthcare Foundation has awarded a $25,000 grant to Integrated Family Community Services (IFCS) in Englewood to support this organization whose work, since its founding in 1964, is focused on alleviating hunger. The grant is one of many awarded across the country as part of HCA Healthcare Foundation’s new Health Equity Catalyst Grant Program. This year, the grants were given to nonprofits addressing food insecurity and providing access to healthy foods. “At Swedish, we’re committed to supporting organizations and collaboratives addressing health inequities,” said Ryan Tobin, CEO, Swedish Medical Center. “Colleagues from our Emergency Department consistently volunteer as a team at IFCS, and recently helped support over 300 community children through the IFCS Helping Hands for the Holidays program.” “Over the years, the population we serve has become much more diverse,” said Todd McPherson, Development Director for IFCS. “Support from the Health Equity Catalyst Grant will enable us to increase training for staff and volunteers around diversity, equity, and inclusion. The grant will also assist IFCS in retaining multiple language speaking staff or translation resources, allowing more outreach to diverse populations that could use support but are unaware of the resources due to language barriers. IFCS will produce marketing and informational materials in multiple languages.” Launched in August 2023, the Health Equity Catalyst Grant Program provides one-time operating grants to support organizations and collaboratives addressing health inequities in a defined focus area in order to advance or accelerate efforts to: • Provide culturally and structurally competent services, In addition to these grants, HealthONE hosted their third-annual Healthy Food for Healthier Tomorrows Food & Nutrition Drive to help fight against food insecurity. This fall, HealthONE, including Swedish Medical Center, provided 5,330 meals to Denver-metro community food banks. In total, HCA Healthcare, its colleagues and the HCA Healthcare Foundation provided more than 1 million nutritious meals to community food banks by donating food or making financial contributions to help purchase perishable items such as milk, fruit and vegetables. The Healthier Tomorrow Fund is a community impact fund focused on addressing high-priority community needs and advancing health equity. Since its launch in 2021, the Healthier Tomorrow Fund has committed more than $18.86 million in communities where HCA Healthcare has a presence and made grants to 79 nonprofit organizations. About Swedish Medical Center As a national leader in neurosciences, Swedish serves as the hub of the Swedish Neuro Network. The hospital is the Rocky Mountain Region’s preeminent referral center for the most advanced stroke treatment and was the state’s first Joint Commission certified Comprehensive Stroke Center. Swedish also is home to Colorado’s first fully comprehensive robotics program with ten robots in dedicated robotics operating rooms; patients benefit from a high level of specialization with robotics-trained caregivers at every stage of treatment, as well as robotics-specific design in the program’s dedicated pre-op, ORs, PACU and inpatient spaces. As the region’s neurotrauma and orthopedic trauma provider and a Level 1 trauma facility, more than 150 facilities regularly transfer highly complex cases to Swedish. The trauma program includes a burn and reconstructive center, which has been certified for adult burn care by the American Burn Association and recognized nationally for providing the highest quality of care to adult and pediatric burn and reconstructive patients. HealthONE Categories Perfect Medical Health Management Limited (the “Company”, Stock Code: 1830.HK), one of the largest aesthetic medical operators in the world, together with its subsidiaries (collectively referred to the “Group”), is pleased to announce its interim results for the six months ended 30 September 2023. RESULTS HIGHLIGHTS — The Group’s revenue increased by 7.5% to HK$718.1 million, thanks to the momentum growth in revenue in Hong Kong and mainland China amid the abatement of the pandemic in early 2023. — The Group’s EBITDA increased by 5.4% to HK$242.1 million. — The Group’s net profit increased by 10.4% to HK$166.4 million, representing a net profit margin of 23.2%. Basic earnings per share were HK13.2 cents. If excluding the one-off government subsidies in the last financial period, the adjusted net profit after tax increased by 27.1%. — The Board recommends the payment of an interim dividend of HK13.2 cents and a special dividend of HK1.0 cents per share to shareholders. — The Group operated a total service area of 297,000 square feet in Hong Kong, mainland China, Macau, Australia and Singapore, with an addition of two shops in Hong Kong during the period. For the period under review, the Group achieved satisfactory results thanks to the meaningful return of new customers and the solid relationship with the loyal customers in both Hong Kong and mainland China. The Group’s revenue increased by 7.5% year-on-year to HK$718.1 million (FY2022/23 interim: HK$668.3 million). The Group’s EBITDA increased by 5.4% year-on-year to HK$242.1 million (FY2022/23 interim: HK$229.7 million). Profit attributable to equity holders of the Company was HK$166.4 million, increased by 10.4% year-on-year (FY2022/23 interim: HK$150.7 million), representing an increase of 0.7 percentage points in net profit margin to 23.2% for the period (FY2022/23 interim: 22.5%). Basic earnings per share were HK13.2 cents (FY2022/23 interim: HK12.1 cents). As of 30 September 2023, the Group operated a total service area of 297,000 square feet in Hong Kong, mainland China and overseas. Hong Kong Operation Revenue from Hong Kong operation increased by 11.6% year-on-year to HK$549.6 million (FY2022/23 interim: HK$492.4 million), overtaking the revenue of Hong Kong operation before pandemic in FY2019/20 interim by 7.2%, thanks to the improvement in shop utilisation and the contribution from the newly established residential shops in Hong Kong. The recovery of revenue to beyond the FY2019/20 interim level demonstrates the Group’s success in recalibrating its business operation. Currently, revenue from Hong Kong operation accounted for 76.5% of the Group’s revenue (FY2022/23 interim: 73.7%). As of 30 September 2023, the Group had a well-established network of service centres in Hong Kong covering a total service area of 192,000 square feet, with an increase of two shops in Tsuen Wan and Taikoo during the period. During the period, the Group witnessed a strong demand for its core aesthetic medical services thanks to the unwavering support by its loyal customers. The Group has recalibrated its business model to further expand its geographical reach in Hong Kong through the introduction of residential shops in medium-to-high end shopping malls and residential locations. As for the core mega shops, the Group saw a welcoming response to the medical tourism flagship centres in Causeway Bay and Tsim Sha Tsui where there was intense demand for its premium medical beauty services by the cross-border customers. At its non-aesthetic medical business, it includes a range of supplementary healthcare management services, including hair growth treatment, pain treatment, health screening service as well as other beauty and wellness services, to fully collaborate with our aesthetic medical services. During the period, the Group enhanced the cross-selling to the medical business following the improvement in our aesthetic medical business. Regions outside Hong Kong Revenue from regions outside Hong Kong decreased by 4.2% year-on-year to HK$168.5 million (FY2022/23 interim: HK$175.9 million), impacted by the lower demand in Singapore and Australia but compensated by the recovery in mainland China. Currently, revenue from the regions outside Hong Kong accounted for 23.5% of the Group’s revenue (FY2022/23 interim: 26.3%). For the period under review, operating profit in mainland China and Macau improved year-on-year thanks to the gradual recovery in customers’ demand and the absence of business suspension in this financial period. As of 30 September 2023, the Group had a network of 22 shops in strategic locations in mainland China and Macau. In the first half of this financial year, the performance of the Australia and Singapore operation was impacted by the sustained inflationary environment and the high living expenses in both countries. It may take some time for the international market to recover. Prospects Dr. Au-Yeung Kong, the executive director, chairman and chief executive officer of Perfect Medical, said that “The promising business performance in the first half of the financial year has demonstrated our superior business model can withstand poor market conditions. We remained steadfast in our core strategy of ‘Healthcare + Medical Beauty’ to satisfy the individual needs of the consumers. As the demand generally bounced back after the three-year pandemic, the rebound in tourist arrivals in Hong Kong this year will bring along additional cross-border customers to the Group, which will reinforce the Group’s determination to become the most favourable aesthetic medical service centres in the Greater Bay Area in the long run. In mainland China, we will closely monitor the market dynamics and economic landscape to better prepare for the economic fluctuation. We spare no effort in optimising our business operation to improve shop productivity to fully capitalise on the rebound in foot traffic at shopping malls. As for the international market, we will proceed with its business development in a prudent and steady manner with relentless dedication to customer satisfaction.” For further information of the Group’s FY2023/24 interim results, please refer to the Company’s Interim Results Announcement on the Hong Kong Stock Exchange website at: https://www1.hkexnews.hk/listedco/listconews/sehk/2023/1124/2023112400233.pdf About Perfect Medical Health Management Limited Perfect Medical Health Management Limited is a multinational aesthetic medical corporate and one of the largest aesthetic medical operators in the world established in 2003. The Group focuses primarily on non-invasive aesthetic medical services and medical services in Hong Kong, China, Macau, Australia and Singapore with a total service area spanning approximately 297,000 square feet as of 30 September 2023. Its operation offers a broad spectrum of professional services with assurance of utmost safety and efficacy. The Company was included as a constituent stock of the MSCI Hong Kong Small Cap Index on 27 May 2021, demonstrating the confidence from the capital market and recognising the investment value of the Company. For further information, please contact: Perfect Medical Health Management Limited Marco So / Peter Kwok Email: ir@perfectmedical.com Tel: (852) 2770 2099 iPR Ogilvy Limited Callis Lau / Tina Law / Rita Chen Email: perfectmedical@iprogilvy.com Tel: (852) 2136 6185 expEDIum Announces Successful Partnership with Medical Billing Service & Long-Term Care Medical Group, Inc.
Established in 1999, Medical Billing Services stands as a seasoned leader in the medical billing industry. With over two decades of expertise, the company has perfected the art of processing thousands of medical billing claims daily. Commitment to accuracy, efficiency, and cutting-edge technology has allowed to navigate the complex landscape of healthcare billing seamlessly. As pioneers in the field, the company prides ourselves on delivering unparalleled service, ensuring that healthcare providers can focus on patient care while handling the intricacies of billing with precision and expertise. Trust Medical Billing Services for a reliable partner in navigating the ever-evolving world of medical billing.
expEDIum is a leading provider of innovative and secure healthcare solutions, offering a comprehensive suite of products designed to streamline medical billing processes and enhance revenue generation for healthcare providers. The comprehensive suite of products is complemented by a 60-day free trial of the billing software, supported by top-notch customer service.
Email: komal@expedium.net, marketing@expedium.net
Phone: 786-646-0099 Ext 1000
www.expedium.net
Sivakumar Narayanaswamy
786-646-0099
www.expedium.net
Contact
China Medical System (00867) Obtained Exclusive License of a First-line Phosphate-lowering Drug Velphoro(R)
1. Drug registration information can be found on the NMPA official website, as follows: https://www.nmpa.gov.cn/datasearch/search-result.html
Or can be found in the public medical insurance materials, as follows
http://www.nhsa.gov.cn/attach/Ypsn2023/YPSW202300180/YPSW202300180-W1(ppt).pdf
2. XQ Yu, et al. Chin J Nephrol, 2018. 34(11): 867-871
3. The Instructions for Sucrose HydroxyIron Oxide Chewable Tablets
4. Coyne DW, et al. Clin Nephrol. 2017 Aug;88(8):59-67.
5. Xie, D., Ye, N. & Li, M., Int Urol Nephrol 50, 905-909 (2018)
6. Floege J, et al. Nephrol Dial Transplant. 2015 Jun;30(6):1037-46
7. Sprague SM,et al.Am J Nephrol. 2016;44(2)104-12
8. Vervloet MG et al. Clin Kidney J 2021;14:1770-9
9. Kalantar-Zadeh K, et al. BMC Nephrol . 2019 0ct 29;20(1):396
10. Kidney Med. 2020 May-Jun; 2(3): 307-316
11. The data of China’s CNRDS reported by academician, Meixiang Chen., on 2023 Annual Conference of Chinese Nephrologist Association.
12. YF Chen, et al. Chin J Blood Purif. 2022; 21(05): 305-308.
13. Kidney International Supplements, 2020, 10(2): e97–185
14. Hong, D. et al. Sci Rep 12, 16694 (2022).
2. The information involved in this news/article is for reference only. Please follow the advice or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Website: https://web.cms.net.cn/en/home/Swedish Medical Center Announces HCA Healthcare Foundation’s $25,000 Grant to Integrated Family Community Services
• Advance high-impact health equity programming,
• Support collaborative health equity efforts, and/or
• Address root causes of health inequities.
Swedish Medical Center is in the south metro Denver area where it has been a proud member of the community for more than 115 years. An acute care hospital with 408 licensed beds, Swedish cares for more than 200,000 patients annually, with a team of approximately 2,000 dedicated employees, 1,400 physicians and 300 volunteers.
Stephanie Sullivan
303-584-8029
www.healthonecares.comContact
Perfect Medical Announces Interim Results for FY2023/24
Topic: Press release summary
Ads
